Perioperative management of biologic agents used in treatment of rheumatoid arthritis

American Journal of Therapeutics

Volumn 18, Issue 5, 2011, Pages 426-434

  Mushtaq, Saulat ^a   Goodman, Susan M ^b   Scanzello, Carla R ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

biologics; DMARDs; perioperative management; rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB;

ARTHROPLASTY; ARTICLE; HEALING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; NONHUMAN; PERIOPERATIVE PERIOD; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SURGICAL INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOLOGIC FACTORS; PERIOPERATIVE CARE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052776250     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181cb4042     Document Type: Article

References (54)

1. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443-1450. (Pubitemid 34620189)
2. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46: 2294-2300.
3. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287-2293.
4. Powers KA, Terpenning MS, Voice RA, et al. Prosthetic joint infections in the elderly. Am J Med. 1990;88:9N-13N.
5. Ahlberg A, Carlsson AS, Lindberg L. Hematogenous infection in total joint replacement. Clin Orthop Relat Res. 1978;137:69-75. (Pubitemid 9108122)
6. Bridges SL Jr, Moreland LW. Perioperative use of methotrexate in patients with rheumatoid arthritis undergoing orthopedic surgery. Rheum Dis Clin North Am. 1997;23:981-993. (Pubitemid 27490252)
7. Poss R, Thornhill TS, Ewald FC, et al. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res. 1984;182:117-126. (Pubitemid 14182851)
8. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992;35:1160-1169.
9. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118: 3537-3545.
10. Hyrich KL, Silman AJ, Watson KD, et al. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004;63:1538-1543. (Pubitemid 39573679)
11. Keane J, Gershon S,Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
12. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570. (Pubitemid 36118917)
13. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39:295-299. (Pubitemid 39050474)
14. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50: 372-379. (Pubitemid 38198820)
15. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009;60:1884-1894.
16. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The soluble TNF receptor sepsis study group. N Engl J Med. 1996;334:1697-1702. (Pubitemid 26193621)
17. Kawaguchi H, Hizuta A, Tanaka N, et al. Role of endotoxin in wound healing impairment. Res Commun Mol Pathol Pharmacol. 1995;89:317-327.
18. Bibbo C. Wound healing complications and infection following surgery for rheumatoid arthritis. Foot Ankle Clin. 2007;12:509-524, vii.
19. Ruyssen-Witrand A, Gossec L, Salliot C, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007;25:430-436. (Pubitemid 47091020)
20. Bongartz T. Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions. J Rheumatol. 2007;34:653-655. (Pubitemid 46641364)
21. Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;55:333-337.
22. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878-883. (Pubitemid 39090217)
23. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther. 2004;19:749-754. (Pubitemid 38496640)
24. Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg. 2008;12:1730-1736; discussion 1736-1737.
25. Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg. 2008;12:1738-1744.
26. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956-962; discussion 962-963. (Pubitemid 46661200)
27. Mor IJ, Vogel JD, da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51:1202-1207; discussion 1207-1210.
28. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350: 2572-2581. (Pubitemid 38758544)
29. White CA, Weaver RL, Grillo-Lopez AJ. Antibodytargeted immunotherapy for treatment of malignancy. Annu Rev Med. 2001;52:125-145.
30. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48:2146-2154. (Pubitemid 36959194)
31. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605-611.
32. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother. 2005;11:189-191. (Pubitemid 41216450)
33. Law JK, Ho JK, Hoskins PJ, et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibodypositive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma. 2005;46: 1085-1089. (Pubitemid 40975032)
34. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Exp Opin Drug Saf. 2005; 4:599-608. (Pubitemid 40723731)
35. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol. 2009;10:816-824.
36. Rehnberg M, Amu S, Tarkowski A, et al. Short-and longterm effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11:R123.
37. Furst DE. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther. 2004;26:1960-1975.
38. Thomay AA, Daley JM, Sabo E, et al. Disruption of interleukin-1 signaling improves the quality of wound healing. Am J Pathol. 2009;174:2129-2136.
39. Mountain DJ, Singh M, Singh K. Interleukin-1betamediated inhibition of the processes of angiogenesis in cardiac microvascular endothelial cells. Life Sci. 2008;82: 1224-1230.
40. Maish GO 3rd, Shumate ML, Ehrlich HP, et al. Interleukin-1 receptor antagonist attenuates tumor necrosis factor-induced alterations in wound breaking strength. J Trauma. 1999;47:533-537. (Pubitemid 29444393)
41. Maish GO 3rd, Shumate ML, Ehrlich HP, et al. Interleukin-1 receptor antagonist attenuates tumor necrosis factor-induced alterations in wound breaking strength. J Trauma. 1999;47:533-537. (Pubitemid 29444393)
42. Thomay AA, Daley JM, Sabo E, et al. Disruption of interleukin-1 signaling improves the quality of wound healing. Am J Pathol. 2009;174:2129-2136.
43. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001; 344:907-916. (Pubitemid 32224400)
44. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907-1915. (Pubitemid 37409707)
45. Westhovens R, Kremer JM, Moreland LW, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009;36:736-742.
46. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54:2807-2816. (Pubitemid 44497759)
47. Nogid A, Pham DQ. Role of abatacept in the management of rheumatoid arthritis. Clin Ther. 2006;28:1764-1778. (Pubitemid 46038531)
48. Ma Y, Lin BR, Lin B, et al. Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacol Sin. 2009;30: 364-371.
49. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an antiinterleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002;46:3143-3150. (Pubitemid 35453522)
50. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebocontrolled trial. Arthritis Rheum. 2004;50:1761-1769. (Pubitemid 38725087)
51. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112:3959-3964.
52. Hashimoto J, Garnero P, van der Heijde D, et al. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. Mod Rheumatol. 2009;19:273-282.
53. Biffl WL, Moore EE, Moore FA, et al. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg. 1996;224:647-664. (Pubitemid 26384888)
54. Hirao M, Hashimoto J, Tsuboi H, et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2009;68:654-657.